National Institute of General Medical Sciences; Amended Notice of Meeting, 40207 [E9-19091]
Download as PDF
<![CDATA[
Federal Register / Vol. 74, No. 153 / Tuesday, August 11, 2009 / Notices
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Institute of General Medical
Sciences; Amended Notice of Meeting
Notice is hereby given of a change in
the meeting of the National Institute of
General Medical Sciences Special
Emphasis Panel, August 17, 2009, 8 a.m.
to August 17, 2009, 5 p.m., National
Institutes of Health, Natcher Building,
Room 3AN12, 45 Center Drive,
Bethesda, MD, 20892 which was
published in the Federal Register on
July 24, 2009, 74 FR 36728.
The meeting has been changed from
August 17, 2009 to August 20, 2009. The
meeting is closed to the public.
Dated: August 4, 2009.
Jennifer Spaeth,
Director, Office of Federal Advisory
Committee Policy.
[FR Doc. E9–19091 Filed 8–10–09; 8:45 am]
BILLING CODE 4140–01–M
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Food and Drug Administration
[Docket No. FDA–2009–N–0664]
Joint Meeting of the Anesthetic and
Life Support Drugs Advisory
Committee and the Drug Safety and
Risk Management Advisory
Committee; Notice of Meeting
AGENCY:
Food and Drug Administration,
HHS.
sroberts on DSKD5P82C1PROD with NOTICES
ACTION:
Notice.
This notice announces a forthcoming
meeting of a public advisory committee
of the Food and Drug Administration
(FDA). The meeting will be open to the
public.
Name of Committees: Anesthetic and
Life Support Drugs Advisory Committee
and the Drug Safety and Risk
Management Advisory Committee.
General Function of the Committees:
To provide advice and
recommendations to the agency on
FDA’s regulatory issues.
Date and Time: The meeting will be
held on September 23, 2009, from 8 a.m.
to 4:30 p.m.
Location: Holiday Inn, The Ballrooms,
Two Montgomery Village Ave.,
Gaithersburg, MD. The hotel phone
number is 301–948–8900.
Contact Person: Kalyani Bhatt, Center
for Drug Evaluation and Research (HFD–
21), Food and Drug Administration,
5600 Fishers Lane, (for express delivery,
VerDate Nov<24>2008
20:51 Aug 10, 2009
Jkt 217001
5630 Fishers Lane, rm. 1093, Rockville,
MD 20857, 301–827–7001, FAX: 301–
827–6776, e-mail:
Kalyani.Bhatt@fda.hhs.gov, or FDA
Advisory Committee Information Line,
1–800–741–8138 (301–443–0572) in
Washington, DC area), codes
3014512529 or 3014512535. Please call
the Information Line for up-to-date
information on this meeting. A notice in
the Federal Register about last minute
modifications that impact a previously
announced advisory committee meeting
cannot always be published quickly
enough to provide timely notice.
Therefore, you should always check the
agency’s Web site and call the
appropriate advisory hotline/phone line
to learn about possible modifications
before coming to the meeting.
Agenda: The committees will discuss
new drug application (NDA) 21–217,
EXALGO (hydromorphone HCl), a
modified-release hydromorphone drug
product indicated for the treatment of
moderate-to-severe pain in opioidtolerant patients.
FDA intends to make background
material available to the public no later
than 2 business days before the meeting.
If FDA is unable to post the background
material on its Web site prior to the
meeting, the background material will
be made publicly available at the
location of the advisory committee
meeting, and the background material
will be posted on FDA’s Web site after
the meeting. Background material is
available at https://www.fda.gov/
AdvisoryCommittees/Calendar/
default.htm. Scroll down to the
appropriate advisory committee link.
Procedure: Interested persons may
present data, information, or views,
orally or in writing, on issues pending
before the committee. Written
submissions may be made to the contact
person on or before September 9, 2009.
Oral presentations from the public will
be scheduled between approximately 1
p.m. to 2 p.m. Those desiring to make
formal oral presentations should notify
the contact person and submit a brief
statement of the general nature of the
evidence or arguments they wish to
present, the names and addresses of
proposed participants, and an
indication of the approximate time
requested to make their presentation on
or before September 1, 2009. Time
allotted for each presentation may be
limited. If the number of registrants
requesting to speak is greater than can
be reasonably accommodated during the
scheduled open public hearing session,
FDA may conduct a lottery to determine
the speakers for the scheduled open
public hearing session. The contact
person will notify interested persons
PO 00000
Frm 00053
Fmt 4703
Sfmt 4703
40207
regarding their request to speak by
September 2, 2009.
Persons attending FDA’s advisory
committee meetings are advised that the
agency is not responsible for providing
access to electrical outlets.
FDA welcomes the attendance of the
public at its advisory committee
meetings and will make every effort to
accommodate persons with physical
disabilities or special needs. If you
require special accommodations due to
a disability, please contact Kalyani
Bhatt at least 7 days in advance of the
meeting.
FDA is committed to the orderly
conduct of its advisory committee
meetings. Please visit our Web site at
https://www.fda.gov/
AdvisoryCommittees/AboutAdvisory
Committees/ucm111462.htm for
procedures on public conduct during
advisory committee meetings.
Notice of this meeting is given under
the Federal Advisory Committee Act (5
U.S.C. app. 2).
Dated: August 3, 2009.
Randall W. Lutter,
Deputy Commissioner for Policy.
[FR Doc. E9–19105 Filed 8–10–09; 8:45 am]
BILLING CODE 4160–01–S
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Health Resources and Services
Administration
Advisory Commission on Childhood
Vaccines; Notice of Meeting
In accordance with section 10(a)(2) of
the Federal Advisory Committee Act
(Pub. L. 92–463), notice is hereby given
of the following meeting:
Name: Advisory Commission on
Childhood Vaccines (ACCV).
Date and Time: September 17, 2009, 1 p.m.
to 5:30 p.m. EDT; September 18, 9 a.m. to 12
p.m. EDT.
Place: Parklawn Building (and via audio
conference call), Conference Rooms G & H,
5600 Fishers Lane, Rockville, MD 20857.
The ACCV will meet on Thursday,
September 17 from 1 p.m. to 5:30 p.m. (EDT)
and Friday, September 18 from 9 a.m. to 12
p.m. (EDT). The public can join the meeting
via audio conference call by dialing 1–800–
369–1791 on September 17 & 18 and
providing the following information:
Leader’s Name: Dr. Geoffrey Evans.
Password: ACCV.
Agenda: The agenda items for the June
meeting will include, but are not limited to:
Updates from the Division of Vaccine Injury
Compensation (DVIC), Department of Justice,
National Vaccine Program Office,
Immunization Safety Office (Centers for
Disease Control and Prevention), National
Institute of Allergy and Infectious Diseases
E:\FR\FM\11AUN1.SGM
11AUN1
]]>Agencies
[Federal Register Volume 74, Number 153 (Tuesday, August 11, 2009)]
[Notices]
[Page 40207]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: E9-19091]
[[Page 40207]]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
National Institute of General Medical Sciences; Amended Notice of
Meeting
Notice is hereby given of a change in the meeting of the National
Institute of General Medical Sciences Special Emphasis Panel, August
17, 2009, 8 a.m. to August 17, 2009, 5 p.m., National Institutes of
Health, Natcher Building, Room 3AN12, 45 Center Drive, Bethesda, MD,
20892 which was published in the Federal Register on July 24, 2009, 74
FR 36728.
The meeting has been changed from August 17, 2009 to August 20,
2009. The meeting is closed to the public.
Dated: August 4, 2009.
Jennifer Spaeth,
Director, Office of Federal Advisory Committee Policy.
[FR Doc. E9-19091 Filed 8-10-09; 8:45 am]
BILLING CODE 4140-01-M
